about
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patientsDosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approachDoes Critical Illness Change Levofloxacin Pharmacokinetics?A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial inA 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy.Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation.Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus.Validation of limited sampling strategy for estimation of mycophenolic acid exposure during the first year after heart transplantation.Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients.Linezolid underexposure in a patient co-treated with venlafaxine.Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site.TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient.Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasisPopulation pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans sppEverolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumoniaStability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperaturesPolytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very
P50
Q33401050-78C17AAB-21A1-46E2-B38F-74F71CA235ACQ34290110-E5CE0EF2-39E2-40F1-AFA0-680ECA52DD09Q35960828-C94FB8A0-5930-4539-8BF0-3F8ECCE82919Q36396195-E07B3D66-06E5-4B2E-960C-107F9D4CC1C0Q36644695-EB165591-DE29-4407-AB6E-0C2EFF900039Q36802059-0866C22D-DAA9-4C1C-891E-F1C3C3EFC93EQ37335720-CA52C853-C43E-4007-9A92-B48A506DA1F1Q40035394-4F151105-5F7F-4948-A7D3-06DAF79382C8Q40317932-0BCD1F62-E769-4C2E-93CA-57F647BFD092Q41349399-4556E087-5998-483D-8977-A42DA35CDC84Q41707035-E226113A-F264-4883-A5BE-28DA724D6E66Q41757518-D1751A1B-97FC-4F01-8B7D-B203BE0C6588Q42719368-1EFB446A-F7EC-4CDB-9FF7-A24FCA4FD280Q43224167-3C6A1204-58F7-4D6D-AD35-A55D3B127702Q43949662-01A60252-E9D8-4272-BBF3-6C3A5DEA4F42Q44123492-C92FD3E9-653F-4819-B99C-524230963EA1Q44455948-1382F12F-6428-4BAF-9582-4E41BB08C310Q46350689-025CF9FC-20AD-4E2D-A989-D7571CE3686FQ54402133-61B421F3-2889-4947-9587-C07E8C3DDF19Q54574842-D3CC2393-A2BA-4322-BD6F-CB9942D8A40BQ57150325-3AB134A1-ED8A-4868-966B-B2EE52F87BF7Q57518396-1590FD5C-3F5F-4ED0-A513-193EED6F5E10Q85946467-CEFE5B67-161B-44D5-AD7D-8C5A2C4A5DEBQ87459116-0250F265-4261-42AE-BBC8-9429A6D8CD28Q89209517-8C98A865-F983-4055-8674-D7F564F62230
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Piergiorgio Cojutti
@en
Piergiorgio Cojutti
@nl
type
label
Piergiorgio Cojutti
@en
Piergiorgio Cojutti
@nl
prefLabel
Piergiorgio Cojutti
@en
Piergiorgio Cojutti
@nl
P31
P496
0000-0001-7135-4410